Episurf Medical

Episurf Medical (Nasdaq: EPIS B) today announces that the abstract "SURVIVORSHIP AND CLINICAL OUTCOMES OF A NOVEL PERSONALIZED METAL IMPLANT FOR THE TREATMENT OF CARTILAGE LESIONS OF THE KNEE", by Dr Francesca de Caro has been accepted for presentation at the ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) congress in Munich, Germany, on June 8-11, 2025. The abstract with up to 10 years' follow-up reports on high implant survival and good clinical outcomes for 34 patients who were treated with Episurf Medical's individualised implant Episealer® Knee, as treatment for chondral and osteochondral defects in the knee. The patients were treated during 2013 - 2023 at AZ Monica Hospital, Antwerp, Belgium.

"The ISAKOS meeting is one of the major international meetings for surgeons active within joint preservation. We are proud to see that our technology continues to get attention and has become a recurring topic at scientific meetings. We also appreciate the engagement from independent study groups. The long-term results they present, with up to 10 years' follow-up, makes our treatment option attractive now also to arthroplasty surgeons, who are used to the long-term results that previously only were available for larger prostheses", says Pål Ryfors, CEO Episurf Medical.